In the BioHarmony Drug Report Database

"Preview" Icon

Perphenazine

Trilafon (perphenazine) is a small molecule pharmaceutical. Perphenazine was first approved as Trilafon on 1982-01-01. It is used to treat huntington disease, nausea, psychotic disorders, reye syndrome, and schizophrenia amongst others in the USA. The pharmaceutical is active against D(2) dopamine receptor. In addition, it is known to target 5-hydroxytryptamine receptor 2C, 5-hydroxytryptamine receptor 6, histamine H1 receptor, 5-hydroxytryptamine receptor 2A, and 5-hydroxytryptamine receptor 7.

 

Trade Name

 

Trilafon
 

Common Name

 

perphenazine
 

ChEMBL ID

 

CHEMBL567
 

Indication

 

huntington disease, nausea, psychotic disorders, reye syndrome, schizophrenia, substance withdrawal syndrome, torticollis, tourette syndrome, vomiting
 

Drug Class

 

Typical antipsychotic

Image (chem structure or protein)

Perphenazine structure rendering